GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants

Antimicrobial Agents and Chemotherapy
Nicole S DelinoHiroaki Mitsuya

Abstract

We identified four novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs), GRL-078, -079, -077, and -058, containing an alkylamine at the C-5 position of P2 tetrahydropyrano-tetrahydrofuran (Tp-THF) and a P2' cyclopropyl (Cp) (or isopropyl)-aminobenzothiazole (Abt) moiety. Their 50% effective concentrations (EC50s) were 2.5 to 30 nM against wild-type HIV-1NL4-3, 0.3 to 6.7 nM against HIV-2EHO, and 0.9 to 90 nM against laboratory-selected PI-resistant HIV-1 and clinical HIV-1 variants resistant to multiple FDA-approved PIs (HIVMDR). GRL-078, -079, -077, and -058 also effectively blocked the replication of HIV-1 variants highly resistant to darunavir (DRV) (HIVDRVrp51), with EC50s of 38, 62, 61, and 90 nM, respectively, while four FDA-approved PIs examined (amprenavir, atazanavir, lopinavir [LPV], and DRV) had virtually no activity (EC50s of >1,000 nM) against HIVDRVrp51 Structurally, GRL-078, -079, and -058 form strong hydrogen bond interactions between Tp-THF modified at C-5 and Asp29/Asp30/Gly48 of wild-type protease, while the P2' Cp-Abt group forms strong hydrogen bonds with Asp30'. The Tp-THF and Cp-Abt moieties also have good nonpolar interactions with protease residues located in the flap ...Continue Reading

References

Nov 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·G PantaleoA S Fauci
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·N E KohlI S Sigal
Jan 1, 1999·Bioorganic & Medicinal Chemistry Letters·A K GhoshJ Buthod
Oct 25, 2000·Protein Science : a Publication of the Protein Society·K StrisovskyH G Kräusslich
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·Terri WatkinsRonald Swanstrom
Aug 22, 2003·Organic & Biomolecular Chemistry·Ashraf Brik, Chi-Huey Wong
Dec 23, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rajesh T GandhiBruce D Walker
Jun 3, 2006·The Journal of Infectious Diseases·Rochelle P WalenskyKenneth A Freedberg
Jul 5, 2007·The Journal of Antimicrobial Chemotherapy·Nicolai LohseNiels Obel
Dec 19, 2007·Advances in Pharmacology·Hiroaki MitsuyaArun K Ghosh
Jan 4, 2013·Cold Spring Harbor Perspectives in Medicine·John Coffin, Ronald Swanstrom
Apr 18, 2014·International Journal of Nanomedicine·Maria João GomesBruno Sarmento
Apr 20, 2016·Trends in Microbiology·Nese Kurt YilmazCelia A Schiffer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

© 2022 Meta ULC. All rights reserved